Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Angela Clemente

Pediatrics House Springs, MO Medical Doctor

NPI 1144290602 CMS profile 97494

100 Osage Executive Cir, House Springs, MO 63051

Open in the dashboard

General payments

$2,791

112 records reported · program years 2019–2021

Research payments

$1,078

Paid to them · 6 records reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Angela Clemente of House Springs, MO is reported in the CMS Open Payments database as having received $2,791 across 112 general payments and $1,078 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $16 1
2020 General $846 46
2019 General $1,929 65
2019 Research $1,078 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Clemente
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Angela Clemente were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Angela Clemente Pediatrics median Middle half National median
2019 $1,929 $86 $31–$183 $163
2020 $846 $49 $22–$110 $114
2021 $16 $68 $27–$158 $132
2022 $0 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Avanir Pharmaceuticals, Inc. $717 8 payments
  2. Sunovion Pharmaceuticals Inc. $560 31 payments
  3. Otsuka America Pharmaceutical, Inc. $296 21 payments
  4. Vanda Pharmaceuticals Inc. $236 11 payments
  5. Janssen Pharmaceuticals, Inc $230 14 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $214 2 payments
  7. Alkermes, Inc. $170 10 payments
  8. Janssen Scientific Affairs, LLC $128 1 payment
  9. Indivior Inc. $42 2 payments
  10. Genentech, Inc. $40 1 payment
  11. Other $159 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $2,188 109 payments
  2. Travel and Lodging $563 2 payments
  3. Education $40 1 payment
Products named General payments · program years 2019–2021
  1. LATUDA $560 31 payments
  2. SPRAVATO $290 12 payments
  3. HETLIOZ $236 11 payments
  4. FANAPT $236 11 payments
  5. REXULTI $169 13 payments
  6. ARISTADA INITIO $152 9 payments
  7. ARISTADA Cns $152 9 payments
  8. ARISTADA Cns $152 9 payments
  9. ARISTADA Cns $152 9 payments
  10. ARISTADA Cns $152 9 payments
  11. Other $542 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,078 6 payments

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record